10 November 2023

Annual Report 2023 Notice of AGM & Proxy Forms

Bioventix plc (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it has today posted its Annual Report for the year ended 30 June 2023 together with a Notice of Annual General Meeting (“AGM”) and Form of Proxy to shareholders that have elected to receive documentation in hard copy format. The documents will also be available to download in PDF format below:

30 June 2023 Annual Report

Notice of AGM

Form of Proxy

The Company’s AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 7 December 2023 at 2.00pm.


For further information please contact:

Bioventix plc
Peter Harrison

Chief Executive Officer

Tel: 01252 728 001

Cavendish Capital Markets Limited
Geoff Nash/Simon Hicks
Nigel Birks/Harriet Ward

Corporate Finance

Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.